Table 2.

Antimicrobial activity of telavancin tested against indicated Gram-positive bacteria listed by geographic region of origin

Regiona	Organism	No. of isolates	MIC (μg/ml)
			MIC50	MIC90	Range
North America	S. aureus	3,488	0.12	0.25	0.03–0.5
	MRSA	1,768	0.12	0.25	0.06–0.5
	E. faecalisb	571	0.5	0.5	0.06–1
	S. pneumoniae	926	≤0.015	0.03	≤0.015–0.12
	BHS	648	0.06	0.12	≤0.015–0.12
	VGS	229	0.03	0.06	≤0.015–0.12
Europe	S. aureus	2,136	0.12	0.25	≤0.015–0.5
	MRSA	497	0.12	0.25	≤0.015–0.5
	E. faecalisb	426	0.5	0.5	0.03–1
	S. pneumoniae	629	≤0.015	0.03	≤0.015–0.06
	BHS	503	0.06	0.12	≤0.015–0.25
	VGS	186	0.03	0.06	≤0.015–0.12
Latin America	S. aureus	914	0.12	0.25	0.03–0.5
	MRSA	400	0.25	0.25	0.06–0.5
	E. faecalisb	239	0.25	0.5	0.03–1
	S. pneumoniae	140	≤0.015	0.03	≤0.015–0.03
	BHS	101	0.06	0.12	≤0.015–0.25
	VGS	32	0.03	0.06	≤0.015–0.12
Asia-Pacific	S. aureus	1,115	0.25	0.5	0.06–0.5
	MRSA	423	0.25	0.25	0.06–0.5
	E. faecalisb	185	0.5	0.5	0.12–1
	S. pneumoniae	455	≤0.015	0.03	≤0.015–0.12
	BHS	220	0.06	0.12	≤0.015–0.25
	VGS	72	0.03	0.06	≤0.015–0.12

^aRegions and countries surveyed were as follows: North America, United States; Europe, Belgium, France, Germany, Ireland, Italy, Poland, Spain, Sweden, United Kingdom, Israel, and Turkey; Latin America, Argentina, Brazil, Chile, and Mexico; Asia-Pacific, Australia, Hong Kong, Japan, Korea, New Zealand, China, Singapore, and Taiwan.

^bAll vancomycin susceptible.